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Worldwide adoption of the Kidney Disease Outcomes Quality
Initiative classification for chronic kidney disease (CKD)
and widespread use of the estimated glomerular filtration
rate to assess renal function have identified large numbers
of patients with previously undiagnosed CKD. It is clear,
however, that this is a heterogeneous group and that only
a small minority of such patients ever progress to end-stage
renal disease. There is thus an urgent need for a simple
method of risk assessment that can be applied to all
patients with CKD to identify those few at greatest risk. The
magnitude of baseline proteinuria has long been recognized
as an important predictor of renal prognosis. Furthermore,
several studies have found that change in proteinuria after
initiation of antihypertensive treatment as well as achieved
level of proteinuria correlate with prognosis. Thus,
proteinuria has emerged as the single most important
marker of renal risk. Many other factors have been identified
as risk factors for CKD progression. Several attempts have
been made to combine a relatively small number of risk
factors into a risk score to predict renal outcomes in specific
groups of patients. Validation of these risk scores as well
as further studies are now required to develop a renal risk
score applicable to a more general population of patients
with CKD. Similar methodology could be applied to assess
the important issue of the cardiovascular risk associated
with CKD.
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Heterogeneity with respect to outcomes is an almost
universal phenomenon across the broad spectrum of human
pathology due to complex interactions between genetic,
environmental, and pathogenic factors. This has important
implications for disease management and clinical decision
making, which often requires careful assessment of the risks
versus benefits of treatments or interventions. In many fields
of medicine, risk evaluation has been formalized through the
use of staging systems (particularly in oncology) or scoring
systems, for example, the Framingham risk score to evaluate
cardiovascular risk or the APACHE II score to assess
prognosis in critically ill patients.
In nephrology, tools for assessing risk are still in their
infancy. The past 5 years have seen welcome advances in
efforts to raise awareness of chronic kidney disease (CKD)
and its consequences. A uniform classification system
proposed by the Kidney Disease Outcomes Quality Initiative
has been adopted worldwide1 and many laboratories now
report estimates of glomerular filtration rate (GFR) derived
from the 4-variable MDRD formula with each measurement
of serum creatinine. Epidemiological studies have found that
CKD is far more prevalent in the general population than
previously appreciated, and latest reports indicate that as
much as 16.8% of the US population may be affected.2 It is
also clear from these data that only a tiny minority of CKD
patients ever advance to end-stage renal disease (ESRD),
implying considerable heterogeneity in the risk of progressive
renal function decline. As the Kidney Disease Outcomes
Quality Initiative classification system is based on GFR alone,
it affords no information regarding the relative risk of
patients within each stage. There is thus an urgent need for
a simple method of risk assessment that can be applied to
all patients with CKD to identify those few at greatest risk.
PROTEINURIA: THE PRINCIPAL RENAL RISK FACTOR
The magnitude of proteinuria is widely recognized as a
marker of the severity of glomerulopathy. A large body of
evidence attests that proteinuria is also the single most
important marker of prognosis in CKD. Population-based
studies have identified proteinuria as a predictor of future
decline in GFR3 and the development of ESRD.4 Even
increases in albuminuria within the normal range have been
associated with increased risk of subsequent overt proteinuria
in subjects with type 2 diabetes.5 Similarly, among subjects
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with diabetic nephropathy6,7 and nondiabetic CKD,8–10 large
prospective trials have confirmed baseline proteinuria as
a strong independent predictor of the rate of GFR decline
or ESRD. The importance of proteinuria as a risk factor
is enhanced by the observation that both proteinuria and
the associated risk of CKD progression may be modified
by therapy. Several studies have reported that the relative
reduction in proteinuria after initiation of renoprotective
treatment and the level of achieved proteinuria are predictors
of the subsequent rate of GFR decline.7,10–12 The same has
recently been shown to be true for microalbuminuria.
Among 216 subjects with type 2 diabetes and microalbumi-
nuria, a return to normoalbuminuria or a 50% reduction
in albuminuria was associated with a significantly lower
risk of a renal or cardiovascular event and a lower subsequent
rate of GFR decline.13 The benefit of minimizing protein-
uria as a therapeutic goal has been confirmed by a pros-
pective trial in which 360 subjects with nondiabetic CKD
were randomized to treatment with a standard dose of
angiotensin-converting enzyme inhibitor (ACEI) or angio-
tensin receptor blocker versus the maximum antiproteinuric
dose of either an ACEI or angiotensin receptor blocker (total
of four randomized groups). For both treatments, subjects
receiving the maximal antiproteinuric dose evidenced
greater reductions in proteinuria (50–53% versus 35–41%)
and a lower incidence of the primary end point of creatinine
doubling, ESRD, or death (17.9 versus 31.3% (P¼ 0.025)
in the ACEI groups; 15.5 versus 29.5% (P¼ 0.022) in the
angiotensin receptor blocker groups) despite equivalent
blood pressure control.14 Moreover, proteinuria predicts
whether or not patients will benefit from ACEI treatment.
In one meta-analysis of data from 1860 subjects with
nondiabetic CKD, ACEI treatment was associated with
additional benefit versus other antihypertensives at all levels
of risk among those with baseline proteinuria X0.5 g day1,
but no additional renoprotection was observed if proteinuria
was o0.5 g day1.15 The importance of proteinuria in
defining renal risk has resulted in a proposal supported by
the UK Consensus Conference on early stage CKD that the
Kidney Disease Outcomes Quality Initiative classification
system for CKD should be modified by the use of a suffix ‘P’
added to the stage to denote patients with significant
proteinuria (41 g day1) and therefore at higher risk of
progression.16 The attraction of such an approach is that it is
simple to apply and requires only a single test that already
forms part of the routine investigation of patients with CKD.
OTHER RENAL RISK FACTORS
Despite the close correlation between the magnitude of
proteinuria and renal outcomes, other factors have been
also been identified as independent predictors of renal prog-
nosis. Indeed, when subjects were subdivided according to
whether or not they evidenced clinically significant protein-
uria, substantial heterogeneity in risk was evident among
subjects with proteinuria X0.5 g day1 and in those with
o0.5 g day1,15 indicating that not all of the risk was
attributable to proteinuria. A large number of independent
risk factors for CKD or CKD progression has been identified
and has been reviewed previously.17 This apparently disparate
list may conveniently be categorized into predisposing,
initiating, and perpetuating factors (Table 1). Studies investi-
gating these factors have provided valuable insights into the
interaction between risk factors and mechanisms of CKD
progression as well as suggesting novel targets for therapeutic
intervention. One recent study has drawn attention to the
important issue of competition between risks of ESRD and
death, which becomes increasingly relevant in older patients
such that among patients aged 65–84 years, the risk of ESRD
exceeded the risk of death only when estimated GFR was
o15 ml per min per 1.73 m2.18 Given the complex patho-
genesis of CKD progression, it is not surprising, however,
that each risk factor accounts for only a relatively small
proportion of the total renal risk. This implies that a
combined assessment of multiple risk factors is required
to obtain a comprehensive assessment of risk. To make such
an approach clinically applicable, it is necessary to identify
a relatively small number of factors that together account for
the majority of the variation in risk.
RENAL RISK SCORES
Some efforts have already been made to combine renal risk
factors into scoring systems that can be used to assess renal
risk in individual patients. One approach has been to use
decision-tree simulation and Bayesian modeling to assess risk
and this has been applied to determine individual risk of
ESRD in a hypothetical population of US patients using
blood pressure and a measure of proteinuria as well as basic
demographic data.19 An alternative method is to employ
multivariate analysis of baseline variables in longitudinal
Table 1 | Risk factors for chronic kidney disease
Predisposing Initiating Perpetuating
Primary renal disease
Urological disorders
Nephrotoxins Nephrotoxins
Older age
Gender
Ethnicity
Family history of CKD
Metabolic syndrome
Hyperfiltration states
Low nephron number kNephron number
Diabetes mellitus
BP4125/75 mm Hg SBP4130 mm Hg
Obesity Obesity
High protein intake High protein intake
Anemia Anemia
mUrinary albumin Proteinuria
Dyslipidemia Dyslipidemia
Cardiovascular disease Cardiovascular disease
Hyperuricemia
Smoking
Hypoproteinemia
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cohort studies to identify independent predictors of
renal outcomes and develop a risk score based on the
coefficients of these variables. Among 1860 subjects with
nondiabetic CKD from a combined database of 11 clinical
trails, Cox proportional hazards analysis identified age,
serum creatinine, proteinuria, and systolic blood pressure
as independent risk factors for the combined endpoint of
time to ESRD or creatinine doubling. A risk model was
developed and used to stratify subjects into quartiles of risk.
In the lowest risk quartile, the annual incidence of the
combined end point was 0.4 versus 28.7% in the highest
quartile for subjects in the control group and 0.2 versus
19.7% for those randomized to ACEI treatment.15 Other
studies have sought to develop risk scores for patients with
specific renal pathologies. Using data from 1513 subjects with
diabetic nephropathy included in the RENAAL study,
multivariate analysis of baseline variables identified urine
albumin/creatinine ratio, serum albumin, serum creatinine,
and hemoglobin as independent risk factors for ESRD.
Analysis of outcomes according to a risk score derived from
the coefficients of these variables revealed a marked difference
in risk between the first and last quartile (event rate 6.7 versus
257.2 per thousand patient years) (Figure 1). The importance
of proteinuria was confirmed by the observation that
albuminuria was the strongest single predictor of ESRD,
but the risk score improved predictive power at least
threefold, especially in low-risk subjects.6 Similarly, multi-
variate analysis of data from 2269 patients with IgA
nephropathy identified systolic blood pressure, proteinuria,
serum total protein, serum creatinine, and histological grade
at initial biopsy as predictors of time to ESRD. Age, gender,
and severity of hematuria were then added to these variables
to develop a scoring system for estimating 4- and 7-year
cumulative incidence of ESRD. There was good agreement
between estimated and observed risks (area under ROC curve
0.939; 95% CI, 0.930–0.964).20
FUTURE PROSPECTS
The studies discussed above demonstrate that it is feasible to
define renal risk in individual patients using a small number
of commonly assessed baseline variables. Each was performed
in a distinct group of subjects with specific forms of CKD, yet
there is remarkable similarity between the variables that
entered the risk prediction models (Table 2). It seems likely
that age, serum creatinine, a measure of proteinuria, systolic
blood pressure, and serum albumin or total protein will be
key variables in future risk scores. Validation of these risk
scores in separate groups of patients is an important next
step. To maximize the clinical applicability of renal risk
scores, it would be desirable to develop a score that could be
applied to a more general population of patients with all
forms of CKD. It is likely that studies of such a patient group
will identify other important predictors of risk that were not
identified in the relatively homogeneous populations studied
to date. For example, diabetes itself may emerge as a risk
factor, but this could not have been identified in a study in
which all patients had diabetes. It is also clear that the above
methodology could readily be applied to the important
additional task of defining cardiovascular risk in patients
with CKD. Large epidemiological studies have drawn
attention to the marked increase in cardiovascular morbidity
and mortality associated with CKD, accounted for only
in part by a high prevalence of traditional cardiovascular
risk factors.21 At present, it is not clear whether or not
cardiovascular risk equations designed to predict outcomes in
the general population are also applicable to those with CKD.
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Figure 1 | Kaplan Meier curve showing the incidence of ESRD
among patients with type 2 diabetes and diabetic nephropathy
included in the Reduction of Endpoints in NIDDM with
Angiotensin II Antagonist Losartan (RENAAL) Study, stratified
into quartiles of a risk score derived from baseline serum
creatinine, urine albumin/creatinine ratio, serum albumin, and
hemoglobin.
Table 2 | Summary of variables used to develop renal risk
scores in different populations of subjects with CKD
Nondiabetic CKD
(n=1860)15
Diabetic nephropathy
(n=1513)6
IgA nephropathy
(n=2269)20
1/serum creatinine Serum creatinine
(mg/dl)
1/serum
creatinine
HR 0.14 (0.11–0.18)
for each 1-SDm
HR 3.59 (2.90–4.45);
w2=137.7
24 h urinary protein
(g/day)
log (UACR) Proteinuria
(dipstick)
HR 1.10 (1.07–1.14) HR 7.12 (4.7–10.8);
w2=85.5
Systolic blood pressure Systolic blood
HR 1.14 (1.09–1.20)
for each 10 mm Hgm
pressure
Serum albumin
(mg/dl)
Serum total
protein
HR 0.46 (0.34–0.62);
w2=25.1
Hemoglobin (mg/dl)
HR 0.90 (0.84–0.96);
w2=10.6
log (Age) Age
HR 0.77 (0.68–0.86)
for each 1-SDm
Gender
Histological
grade
Hematuria
HR, hazard ratio; UACR, urine albumin to creatinine ratio.
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There is thus an opportunity to simultaneously develop both a
renal risk score and a cardiovascular risk score applicable to
CKD patients. Both are urgently required to facilitate targeted
treatment of those at high risk, while avoiding unnecessary
treatment and the attendant financial costs in low-risk patients.
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